The Peritoneal Cancer Index is a Strong Predictor of Incomplete Cytoreductive Surgery in Ovarian Cancer

Björg Jónsdóttir, MD1, Marta Lomnytska, MD, PhD1,2,3, Inger Sundström Poromaa, MD1, Ilvars Silins, MD1, and Karin Stålberg, MD, PhD1

1Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden; 2Department of Obstetrics and Gynecology, Uppsala University Hospital, Uppsala, Sweden; 3Institute of Oncology and Pathology, Karolinska Institutet, Karolinska, Stockholm, Sweden

ABSTRACT

Background. Extent of tumor load is an important factor in the selection of ovarian cancer patients for cytoreductive surgery (CRS). The Peritoneal Cancer Index (PCI) gives exact information on tumor load but still is not standard in ovarian cancer surgery. The aim of this study was to find a PCI cutoff for incomplete CRS. The secondary aims were to identify reasons for open-close surgery and to compare surgical complications in relation to tumor burden.

Methods. The study included 167 women with stage III or IV ovarian cancer scheduled for CRS. Possible predictors of incomplete surgery were evaluated with receiver operator curves, and a PCI cutoff was identified. Surgical complications were analyzed by one-way analysis of variance and Chi square tests.

Results. The median PCI score for all the patients was 22 (range 3–37) but 33 (range 25–37) for the patients with incomplete surgery (n = 19). The PCI predicted incomplete CRS, with an area under the curve of 0.94 (95% confidence interval [CI], 0.91–0.98). Complete CRS was obtained for 67.2% of the patients with a PCI higher than 24, who experienced an increased rate of complications (p = 0.008). Overall major complications were found in 16.9% of the cases. Only 28.6% of the patients with a PCI higher than 33 achieved complete CRS. The reason for open-close surgery (n = 14) was massive carcinomatosis on the small bowel in all cases.

Conclusion. The study found PCI to be an excellent predictor of incomplete CRS. Due to a lower surgical success rate, the authors suggest that neoadjuvant chemotherapy could be considered if the PCI is higher than 24. Preoperative radiologic assessment should focus on total tumor burden and not necessarily on specific regions.

Ovarian cancer, the fourth most common cause of cancer-related death among women, is diagnosed for 240,000 women globally every year.1 The 5-year survival rate in Sweden has been increasing in recent years and currently is 49%.2 At diagnosis, the majority of patients have stages III or IV disease according to the International Federation of Gynecology and Obstetrics (FIGO) staging system,3 meaning that the tumor has disseminated into the peritoneal cavity and its organs.4

The mainstay of treatment is cytoreductive surgery (CRS), with the aim of removing all macroscopic tumors because the absence of any residual disease is the most important factor for survival and prognosis.5 Massive ascites production, poor nutrition status, and significant pleural effusion usually are associated with extensive disease spread, in which case, the patient is assigned to neoadjuvant chemotherapy (NACT). Furthermore, NACT candidates also are patients with nonresectable carcinomatosis, sometimes determined after laparotomy (open-close surgery). Consequently, identifying these patients preoperatively is of great value.6

© The Author(s) 2020
First Received: 25 January 2020; Published Online: 29 May 2020
B. Jónsdóttir, MD
e-mail: bjorjon@gmail.com
Currently, the extent of tumor load is estimated by different imaging methods, usually by computed tomography (CT) and magnetic resonance imaging (MRI) or preoperative laparoscopy. However, no universally accepted reference standard exists for the imaging of peritoneal carcinomatosis.\textsuperscript{7}

To describe peritoneal carcinomatosis, the Peritoneal Cancer Index (PCI) was introduced by Jacquet and Sugarbaker\textsuperscript{8} initially for carcinomatosis of colorectal cancer and mesothelioma. In colorectal cancer, PCI is the most important prognostic factor, showing a linear relationship with overall survival.\textsuperscript{9} A consensus on a cutoff value for treatment has not been clearly established. However, surgery is not recommended for patients who have colorectal carcinomatosis, with a PCI higher than 20.\textsuperscript{10} In ovarian cancer, assessment of PCI still is not a standard of care in clinical practice or in surgical studies.

Different cutoffs of total PCI have been applied for the investigation of resectability and survival in ovarian cancer. For these outcomes, most studies have used PCI cutoffs of 10–15.\textsuperscript{11–13} Furthermore, it has been suggested that instead of the total PCI score, selected PCI regions, such as the small intestine and the hepatoduodenal ligaments, are better predictors for resectability and survival.\textsuperscript{14} Unfortunately, these areas are difficult to assess on preoperative imaging, especially regarding diffuse carcinomatosis on the intestines.\textsuperscript{15}

If information on tumor load from PCI were accurately estimated preoperatively, it could be used in selecting patients for primary surgery. In an attempt to achieve this, the PCI has been used in the interpretation of images.\textsuperscript{16–18} Currently, it is not known whether the PCI cutoff score for colorectal cancer can also be applied for ovarian cancer.

Establishment of a PCI cutoff for CRS in ovarian cancer would be of great value for identifying inoperable patients. This primary aim of this study was to find a PCI cutoff for incomplete CRS. The secondary aims were to identify reasons for open-close surgery and to compare surgical complications in relation to tumor burden.

**MATERIALS AND METHODS**

This single-center study analyzed patients with ovarian, fallopian tube, or primary peritoneal cancer (later referred to as ovarian cancer) treated at Uppsala University hospital, an ESGO-certified tertiary referral center that performs 70–80 primary ovarian cancer operations per year.

The preoperative workup included diagnosis based on histology and/or on cytology and a tumor marker profile suggesting gynecologic cancer. A CT scan of the abdomen, pelvis, and thorax (chest) was an obligatory part of the workup. Patients were selected for neoadjuvant chemotherapy (NACT) on the basis of poor general condition, advanced age, massive ascites, hypoalbuminemia, significant pleural effusion, or other factors indicating massive disease spread (e.g., major carcinomatosis on the CT scan).

The inclusion criteria specified women who had suspected ovarian cancer with carcinomatosis, recorded data on estimated PCI during surgery, and disease in the range of FIGO stages IIIB to IVB. Women who previously had undergone open-close surgery and received NACT were not included in the study.

Data on FIGO stage, histology, patient characteristics, surgery, and surgical complications were collected from the medical records. A certified gynecologic cancer surgeon participated in all the operations. The study was approved by the Swedish Ethical Review Board (Dnr 2018/071, Dnr 2019/05513).

**Peritoneal Cancer Index and Cytoreduction Score**

Surgery was performed with the intention of achieving complete cytoreduction. At the beginning of the surgery, a PCI score was estimated as follows. For the anatomic distribution, 13 regions were defined. Two transverse planes and two sagittal planes divide the abdominopelvic cavity into nine regions. Regions 9–12 divide the small bowel. Lesion size (LS) refers to the greatest diameter of the tumor implants distributed on the peritoneal surfaces, with LS ranging from 0 (no tumor seen) to 3 (tumor > 5 cm). The PCI score ranges from 0 to 39 (Supplementary Data 1).\textsuperscript{8}

At completion of the surgery, the completeness of the cytoreduction score (CCS) was estimated as follows: CC0 (no residual disease), CC1 (residual nodules < 2.5 mm), CC2 (residual nodules between 2.5 mm and 2.5 cm), and CC3 (residual nodules > 2.5 cm). Complete cytoreduction was defined as CC0 and CC1, whereas CC2 and CC3 were considered to indicate incomplete cytoreduction. If the surgeon did not see any possibility for radical or near radical surgery, no surgery was performed, the abdomen was closed (open-close procedure), and the procedure was classified as incomplete cytoreduction.

To evaluate the complexity of operations, the Aletti score was used, which divided the operations into three groups using low, intermediate, or high complexity scores. These scores are based on the number of procedures performed in every operation and their degree of difficulty.\textsuperscript{19}

The 30-day postoperative complications were graded with the Clavien–Dindo classification system.\textsuperscript{20}
Statistical Analyses

The PCI cutoff values for incomplete CRS were evaluated with a receiver operator characteristic (ROC) curve and other possible predictors of incomplete CRS explored with ROC curves. The predictors tested were age, preoperative albumin levels, body mass index, smoking, American Society of Anesthesiologists [ASA] score, physical status classification system, FIGO stage, treatment, histology, and PCI score. Subgroups identified by PCI cutoff were compared regarding peri- and postoperative complications using an independent t test, Chi square tests, or one-way analysis of variance (ANOVA). Patient characteristics, divided into groups by completion of CRS, were compared with an independent t test and Chi square tests. A two-sided p value lower than 0.05 was considered statistically significant. The data were analyzed using IBM SPSS statistics 24 (IBM Corp., Armonk, NY, USA).

RESULTS

The study enrolled 204 women scheduled for primary or interval CRS from 1 January 2014 to 15 October 2018 at Uppsala University Hospital. The study excluded 29 women due to a FIGO stage lower than IIIB or because of histology types other than epithelial ovarian, fallopian tube, or primary peritoneal cancer. Seven women were excluded due to missing registration of PCI (Fig. 1). Thus, 167 women were included in the study. None of the women had undergone preoperative laparoscopy.

Clinical variables and tumor characteristics of the study population are described in Table 1. The majority of the patients had high-grade serous adenocarcinoma and FIGO stage IIIC or IV disease, and 48.5% had received neoadjuvant chemotherapy (NACT).

The median PCI score for the entire study population was 22 (range 3–37; interquartile range [IQR] 12–27). Complete CRS was achieved for 148 patients (88.1%), corresponding to CC0 in 121 cases (82%). Of 19 patients who had incomplete CRS, 14 underwent open-close surgery because of inoperability due to massive carcinomatosis on the small bowel. For the remaining five patients, CRS resulted in CC2-3 despite surgical effort that found carcinomatosis at the end of surgery on the surface of the small bowel or basal pleura or on the main artery of the liver. One patient was judged too weak for completion of the larger surgery because of a preoperative pulmonary embolism.

Patients with an incomplete CRS had a higher median PCI of 33 (range 25–37; IQR 30–35), whereas those with a complete CRS had a median PCI of 19 (range 3–34; IQR 12–25) (p < 0.001; Table 1).

Predictors for incomplete CRS were determined by ROCs. According to these analyses, the best predictor of incomplete CRS was the intraoperative PCI score with an AUC of 0.945 (95% confidence interval [CI], 0.91–0.98; Table 2; Fig. 2a). None of the remaining variables could predict incomplete CRS, and all AUCs were lower than 0.6 (Table 2). Furthermore, the addition of primary treatment and body mass index (BMI) to the PCI score minimally improved the predictive value (AUC, 0.953; 95% CI, 0.92–0.98; Fig. 2b).
Based on these analyses, two cutoffs were established. First, a PCI score of 24 or lower had a sensitivity of 100% for detection of cases with incomplete CRS. The specificity of a PCI cutoff score higher than 24 was 73.6% because many patients above this cutoff still remained operable. Overall, 39 patients (67.3%) with a PCI score higher than 24 had a complete CRS. Second, to obtain high specificity for detecting cases of incomplete CRS, a PCI cutoff of 33 was identified, at which the sensitivity and specificity for incomplete CRS cases were respectively 45.0% and 99.3%. Among the patients with a PCI higher than 33, 71.4% had incomplete operations.

In Table 3, the surgical complexity and complications are analyzed by dividing the study population into three groups using the two cutoff levels. No difference regarding histology or FIGO stage was found, although the tendency in the group with a PCI of 33–37 was that fewer patients had received NACT. Overall, the Aletti surgical complexity score (SCS) was high (≥ 8) for 71.2% of the patients, and the stoma rate was 45.1%, including end ileostomies, loop ileostomies, and colostomies. Major complications (Clavien–Dindo grade 3 or higher) were found in 16.9% of the cases. In one case, the patient died within 30 days after surgery. Other common major

TABLE 1 Patient and tumor characteristics in the entire study population and in relation to completeness of cytoreductive surgery (CRS)\(^a\)

|                         | All patients (n = 167) | Complete CRS (n = 148) | Incomplete CRS (n = 19)\(^b\) | p value |
|-------------------------|------------------------|------------------------|-----------------------------|---------|
| Age: years (IQR)        | 64 (55–71)             | 65 (55–71)             | 59 (55–65)                  | 0.3     |
| Albumin: g/l (IQR)      | 35.0 (32.0–37.0)       | 35.0 (32.0–37.0)       | 33.0 (32.0–36.0)            | 0.7     |
| BMI (kg/m\(^2\))        |                        |                        |                             | 0.07    |
| < 20.0                  | 1 (0.6)                | 1 (0.7)                | 0                           |         |
| 20.0–25.0               | 86 (51.8)              | 72 (49.0)              | 14 (73.7)                   |         |
| 26.0–30.0               | 41 (24.7)              | 36 (24.5)              | 5 (26.3)                    |         |
| > 30.0                  | 38 (22.9)              | 38 (25.9)              | 0                           |         |
| Smoking                 |                        |                        |                             | 0.3     |
| No                      | 141 (85.5)             | 125 (84.5)             | 16 (94.1)                   |         |
| Yes                     | 24 (14.5)              | 23 (15.5)              | 1 (5.9)                     |         |
| ASA score               |                        |                        |                             | 0.7     |
| 10                      | 10 (6.1)               | 10 (6.8)               | 0                           |         |
| 20                      | 108 (65.5)             | 95 (64.6)              | 13 (72.2)                   |         |
| 30                      | 46 (27.9)              | 41 (27.9)              | 5 (27.8)                    |         |
| 40                      | 1 (0.6)                | 1 (0.7)                | 0 (0)                       |         |
| FIGO stage              |                        |                        |                             | 0.6     |
| IIIB                    | 2 (1.2)                | 2 (1.4)                | 0                           |         |
| IIIC                    | 86 (51.5)              | 78 (52.7)              | 8 (42.1)                    |         |
| IV                      | 79 (47.3)              | 68 (45.9)              | 11 (57.9)                   |         |
| Primary treatment       |                        |                        |                             | 0.3     |
| Primary surgery         | 86 (51.5)              | 74 (50.0)              | 12 (63.2)                   |         |
| NACT                    | 81 (48.5)              | 74 (50.0)              | 7 (36.8)                    |         |
| Histology               |                        |                        |                             | 0.9     |
| HGSC                    | 140 (83.8)             | 123 (83.1)             | 17 (89.5)                   |         |
| Endometrioid            | 3 (1.8)                | 3 (2.0)                | 0 (0)                       |         |
| Clear cell              | 7 (4.2)                | 6 (4.1)                | 1 (5.3)                     |         |
| LGSC                    | 14 (8.4)               | 13 (8.8)               | 1 (5.3)                     |         |
| Carcinosarcoma          | 3 (1.8)                | 3 (2.0)                | 0 (0)                       |         |
| PCI                     | 22.0 (12.0–27.0)       | 19.0 (12.0–25.0)       | 33.0 (30.0–35.0)            | < 0.001 |

IQR, interquartile range; BMI, body mass index; ASA, American Society of Anesthesiology; FIGO, International Federation of Gynecology and Obstetrics; NACT, neoadjuvant chemotherapy; HGSC, high-grade serous adenocarcinoma; LGSC, low-grade serous adenocarcinoma
\(^a\)Percentages are presented in relation to available information. Missing information in 0–6 of variables. Statistics were obtained by independent t tests or Chi square tests
\(^b\)Incomplete CRS is defined as Completeness of Cytoreductive Score (CCS) 2 or 3
The rate of peri- or postoperative complications was increased in both cutoff groups ($p = 0.024$), with major complications for 27% of the group with a PCI of 25–32 and 42.9% of the group with a PCI of 33–37. The operation time, SCS, and blood loss increased with a higher PCI. The duration of surgery was 1.7 times longer for the group with a PCI of 33–37 than for the group with a PCI of 1–24. The stoma rate was 30.3% for the patients with a PCI lower than 24 compared with 81.1% and 85.7% for the groups with the higher PCI (Table 3).

**DISCUSSION**

In our cohort of patients with advanced ovarian, fallopian tube, and peritoneal cancer, the intraoperative PCI score was found to be an excellent predictor of incomplete CRS. All the patients in the study population with incomplete surgery had a PCI higher than 25, and the reason for open-close surgery in all cases was carcinomatosis on the small bowel.

A limitation of our study was that it included few cases with incomplete surgery. Its strengths were the homogeneity of the patients, surgeries at one center performed in a standardized manner by two certified gynecologic cancer surgeons, and a perioperative PCI evaluated at the time of each surgery. However, the homogeneity of the patients also may also be considered a limitation because it makes generalization to other centers more difficult.

Various PCI cutoff values for indicating incomplete CRS have been discussed. Llueca et al.\(^{21}\) suggested that ovarian cancer patients with a PCI higher than 20 should be assigned to NACT because of complication risks. Lampe et al.\(^{22}\) suggested that complete CRS can be achieved up to a maximum PCI of 25. Older studies analyzing PCI as a predictor of survival have suggested lower cutoff values of 10\(^{11}\) and 13,\(^{23}\) with worse prognosis associated with a higher PCI. These studies resulted in more extensive surgery. The current study found that complete cytoreduction can be obtained for patients with a PCI up to 34.

Compared with many previous studies, the current study population had a higher tumor load, as indicated by the median PCI of 22, and 45% of the patients had stage IV disease.

At Uppsala University Hospital, surgery is performed for 70–80 primary ovarian cancer patients per year, and a complete CRS rate of 88.1% has been achieved, which is
During the study period, we had a stoma rate of 45% and a major complication rate of 16.7%. The stoma rate was 30% for low PCI (< 25) versus 81% for high PCI (> 25), which might be considered acceptable when weighted against the expected survival benefit of radical surgery. The criteria for stoma formation in our clinic are poor nutrition, hypoalbuminemia, multiple bowel resection, steroid usage, and other factors that increase the risk of anastomosis leakage. However, during and after the study period, we became more restrictive with stoma formation.

All the patients in our study with a PCI of 24 or lower had a complete CRS, with 88% experiencing minor complications. Complete CRS was reached for 67.3% of the patients with a PCI of 25–34, but 29.6% of this group had grade 3 or 4 complications, and 81.8% received a stoma. Consequently, patients with a PCI higher than 24 could benefit from neoadjuvant chemotherapy. However, the

### TABLE 3 Peri- and postoperative complications according to Peritoneal Cancer Index (PCI) cutoffs

|                      | PCI 1–24 (n = 109) | PCI 25–32 (n = 44) | PCI 33–37 (n = 14) | p value |
|----------------------|--------------------|--------------------|--------------------|---------|
| **Primary treatment**|                    |                    |                    |         |
| Primary surgery      | 48 (44.0)          | 27 (61.4)          | 11 (78.6)          | 0.016   |
| NACT                 | 61 (56.0)          | 17 (38.6)          | 3 (21.4)           |         |
| FIGO stage           |                    |                    |                    | 0.460   |
| IIIB                 | 2 (1.8)            | 0                  | 0                  |         |
| IIIC                 | 60 (55.0)          | 21 (47.7)          | 5 (35.7)           |         |
| IV                   | 47 (43.1)          | 23 (52.3)          | 9 (64.3)           |         |
| Completeness of surgery |                |                    |                    | 0.000   |
| Complete CRS (CC0-1) | 109 (100)          | 35 (79.5)          | 4 (28.6)           |         |
| Incomplete CRS (CC2-3) |                | 9 (20.5)           | 10 (71.4)          |         |
| **Surgical patients**|                    |                    |                    | 0.004   |
|                      | (n = 109)          | (n = 37)           | (n = 7)            |         |
| Primary treatment    |                    |                    |                    |         |
| Primary surgery      | 48 (44.0)          | 24 (64.9)          | 6 (85.7)           |         |
| NACT                 | 61 (56.0)          | 13 (35.1)          | 1 (14.3)           |         |
| Mean surgery duration: min (range) | 282 (110–609) | 416 (258–710) | 493 (160–823) | 0.000   |
| Mean blood loss: ml (range) | 481 (20–2000) | 635 (200–1500) | 821 (250–1500) | 0.005   |
| SCS                  |                    |                    |                    | 0.005   |
| Low (< 3)            | 9 (8.3)            | 0                  | 0                  |         |
| Intermediate (4–7)   | 32 (29.4)          | 2 (5.4)            | 1 (14.3)           |         |
| High (> 8)           | 68 (62.4)          | 35 (94.6)          | 6 (85.7)           |         |
| Clavien–Dindo        |                    |                    |                    | 0.024   |
| 0                    | 63 (57.8)          | 10 (27.0)          | 2 (28.6)           |         |
| 1                    | 0                  | 1 (2.7)            | 0                  |         |
| 2                    | 33 (30.3)          | 16 (43.2)          | 2 (28.6)           |         |
| 3a                   | 7 (6.4)            | 6 (16.2)           | 1 (14.3)           |         |
| 3b                   | 2 (1.8)            | 1 (2.7)            | 0                  |         |
| 4a                   | 3 (2.8)            | 3 (8.1)            | 2 (28.6)           |         |
| 5                    | 1 (0.9)            | 0                  | 0                  |         |
| Stoma                | 33 (30.3)          | 30 (81.1)          | 6 (85.7)           | 0.000   |
| Ileostomy            | 16 (14.7)          | 14 (37.8)          | 4 (57.1)           |         |
| Colostomy            | 17 (15.6)          | 16 (43.2)          | 2 (28.6)           |         |

NACT, neoadjuvant chemotherapy; FIGO, International Federation of Gynecology and Obstetrics; CRS, cytoreductive surgery; SCS, surgical complexity score

*Statistics were obtained by one-way analysis of variance (ANOVA) or Chi square tests

*Inoperable patients (open-close) were excluded
decision to perform surgery will never be based on carcinomatosis alone. Additional factors such as comorbidity, age, and the patient’s own will should be considered. Furthermore, the question of patient selection for NACT or PDS should be answered by randomized controlled trials such as the forthcoming Trial of Radical Upfront Surgical Therapy (TRUST).25

Attempts have been made to use PCI to predict operability before opting for CRS. Most studies have focused on imaging, whereas Llueca et al.21 have suggested a combination of CT scan and laparoscopy. A laparoscopy scoring system has been introduced,26 but the most crucial areas for resectability may be difficult to access with laparoscopy, resulting in hidden areas of carcinomatosis,27 making it less feasible. A recent Cochrane review28 concluded that laparoscopy could be a useful tool for identifying women with nonresectable disease, but the reviewed studies included women who had incomplete surgery, with laparoscopy predicting total resectability. Moreover, in recent years, CRS has become more extensive, making evaluation with laparoscopy more difficult. The usual limitations for laparoscopy are the presence of obstructing omental cake and adhesions, whereas a tear in the (often fragile) bowel during dissection might be hazardous. Laparoscopy also is connected with the risk of abdominal wall metastasis and disease upstaging.29

Imaging studies have shown that diffusion MRI is superior to CT scan because it provides greater accuracy, whereas CT underestimates small carcinomatosis nodules. However further studies are needed before preoperative patient selection is based on PCI, and our group has an ongoing study on this issue.

In conclusion, the PCI proved to be an excellent predictor of incomplete CRS, and more complications were found with a greater tumor burden. The PCI cutoff of 24 or higher was related to incomplete CRS and inoperability, and we suggest that with this PCI cutoff, neoadjuvant chemotherapy can be considered, especially for fragile patients. Our findings support further studies on PCI in preoperative imaging because more accurate knowledge of tumor load could enhance patient selection before surgery. We recommend that the PCI be used as a standard parameter in clinical management of advanced gynecologic cancers and included as a parameter in registers and research.

ACKNOWLEDGMENT Open access funding provided by Uppsala University. This study was partially funded by the Lions Cancer Foundation and the Erik, Karin and Gösta Selanders Foundation.

DISCLOSURE There are no conflicts of interest.

OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

REFERENCES

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.
2. NORDCAN AotNCR. Cancer stat fact sheet. Retrieved December 12, 2019 at http://www-dep.iarc.fr/NORDCAN/SW/table23.asp?registry=752&sex=2&times=5&sort=0&submit=9%A0%0Ut%F6r%A0%0.
3. Heintz APM, Olicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the Ovary. Int J Gynecol Obstet. 2006;95:161–92.
4. Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet. 2014;124:1–5.
5. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovarie (GINECO). Cancer. 2009;115:1234–44.
6. Eggink FA, Koopmans CM, Nijman HW. Surgery for patients with newly diagnosed advanced ovarian cancer: which patient, when and extent? Curr Opin Oncol. 2017;29:351–8.
7. Forstner R. Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI. Eur Radiol. 2007;17:3223–35.
8. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH (ed) Peritoneal carcinomatosis: Principles of management. Boston: Springer, 1996, pp 359–74.
9. Faron M, Macovei R, Goere D, Honore C, Benhaim L, Elias D. Linear relationship of Peritoneal Cancer Index and survival in patients with peritoneal metastases from colorectal cancer. Ann Surg Oncol. 2016;23:114–9.
10. Simkens GA, Rovers KP, Nienhuis SW, de Hingh IH. Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer. Cancer Manag Res. 2017;9:259–66.
11. Tentes AAK, Triprianis G, Markakis SK, Karanikiotis CN, Tzegas G, Georgiadis G, et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. EJSO Eur J Surg Oncol. 2003;29:69–73.
12. Chereau E, Ballester M, Selle F, Cortez A, Darai E, Rouzier R. Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer. Am J Obstet Gynecol. 2010;202:178e1–e10.
13. Di Giorgio A, De Iaco P, De Simone M, Garofalo A, Scambia G, Pinna AD, et al. Cytoreduction (peritoneectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: retrospective Italian
multicenter observational study of 511 cases. Ann Surg Oncol. 2017;24:914–22.
14. Rosendahl M, Harter P, Bjorn SF, Hogdall C. Specific regions, rather than the entire Peritoneal Carcinosis Index, are predictive of complete resection and survival in advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2018;28:316–22.
15. Fischerova D, Burgetova A. Imaging techniques for the evaluation of ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2014;28:697–720.
16. Torkzad MR, Casta N, Bergman A, Ahlstrom H, Pahlman L, Mahteme H. Comparison between MRI and CT in prediction of peritoneal carcinomatosis index (PCI) in patients undergoing cytoreductive surgery in relation to the experience of the radiologist. J Surg Oncol. 2015;111:746–51.
17. Esquivel I, Chua TC, Stojadinovic A, Melero JT, Levine EA, Gutman M, et al. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol. 2010;102:565–70.
18. Mazzei MA, Khader L, Cirigliano A, Squitieri N, Guerrini S, Forzoni B, et al. Accuracy of MDCT in the preoperative definition of Peritoneal Cancer Index (PCI) in patients with advanced ovarian cancer who underwent peritoneectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Abdom Imaging. 2013;38:1422–30.
19. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007;197:676e1–7.
20. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
21. Lluca A, Serra A, Rivadulla I, Gomez L, Escrig J, group Mw. Prediction of suboptimal cytoreductive surgery in patients with advanced ovarian cancer based on preoperative and intraoperative determination of the peritoneal carcinomatosis index. World J Surg Oncol. 2018;16:37.
22. Lampe B, Kroll N, Piso P, Forner DM, Mallmann P. Prognostic significance of Sugarbaker’s Peritoneal Cancer Index for the operability of ovarian carcinoma. Int J Gynecol Cancer. 2015;25:135–44.
23. Elzarkaa AA, Shaalan W, Elemam D, Mansour H, Melis M, Malik E, et al. Peritoneal Cancer Index as a predictor of survival in advanced-stage serous epithelial ovarian cancer: a prospective study. J Gynecol Oncol. 2018;29:e47.
24. Fotopoulou C, Jones BP, Savvatis K, Campbell J, Kyrgiou M, Farthing A, et al. Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities. Arch Gynecol Obstet. 2016;294:607–14.
25. Reuss A, du Bois A, Harter P, Fotopoulou C, Schoili J, Aletti G, et al. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). Int J Gynecol Cancer. 2019;29:1327–31.
26. Fagotti A, Ferrandina G, Fanhani F. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol. 2006;13:1156–61.
27. Passot G, Dumont F, Goeré D, Arvieux C, Rousset P, Regimbeau JM, et al. Multicentre study of laparoscopic or open assessment of the peritoneal cancer index (BIG-RENAPE). Br J Surg. 2018;105:663–7.
28. van de Vrie R, Rutten MJ, Asseler JD, Leeflang MM, Kenter GG, Mol BWJ, et al. Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer. Cochrane Database Syst Rev. 2019;3:CD009976.
29. Ataseven B, Grimm C, Harter P, Heikaus S, Heitz F, Traut A, et al. Prognostic impact of port-site metastasis after diagnostic laparoscopy for epithelial ovarian cancer. Ann Surg Oncol. 2016;23(Suppl 5):834–40.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.